# Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)

> **NCT04604691** · PHASE1 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Pediatric ALL, B Cell
- Minimal Residual Disease

## Interventions

- **DRUG:** Blinatumomab for Injection

## Key facts

- **NCT ID:** NCT04604691
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-18
- **Primary completion:** 2023-03
- **Final completion:** 2024-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04604691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04604691, "Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04604691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*